dabigatran has been researched along with Chronic Kidney Diseases in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 42 (70.00) | 24.3611 |
| 2020's | 18 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zakrocka, I; Załuska, W | 1 |
| Brewster, J; Hingorani, AD; Lau, WCY; Li, J; Lip, GYH; Man, KKC; Reich, C; Seager, S; Stewart, HM; Torre, CO; Van Zandt, M; Wei, L; Wong, ICK | 1 |
| Badve, SV; Deague, J; Dundon, BK; Hammett, C; Joseph, JE; Kerr, PG; Lo, S; Perkovic, V; Tran, HA; Wong, A | 1 |
| Boivin Proulx, LA; Dorais, M; Legault, C; Lenglet, A; Perreault, S; Qazi, JZ | 1 |
| Andrade, JG; Fordyce, CB; Holmes, DN; Levin, A; Piccini, JP; Yao, RJR | 1 |
| Achanta, A; Bhalodia, NJ; Cheng, J; Coons, JC; Deri, CR; Heiney, H; Iasella, CJ; Marchionda, O; Stahl, K; White, EM | 1 |
| Angiolillo, DJ; Capranzano, P | 1 |
| Khedraki, R; Muse, ED; Steinhubl, SR | 1 |
| Jairam, A; Jha, VK; Mahapatra, D | 1 |
| Aimo, A; De Caterina, R; Petricciuolo, S | 1 |
| Bochkov, P; Fomin, V; Gurinovich, O; Ivashchenko, D; Kogay, V; Krainyaya, A; Krupenin, P; Listratov, A; Napalkov, D; Ryzhikova, K; Shevchenko, R; Skripka, A; Sokolova, A; Sychev, D | 1 |
| Bochkov, P; Fomin, V; Gurinovich, O; Kogay, V; Krainyaya, A; Krupenin, P; Listratov, A; Napalkov, D; Shevchenko, R; Skripka, A; Sokolova, A; Sychev, D | 1 |
| Ashley, J; Badve, SV; Battistella, M; Bota, S; Garg, AX; Harel, Z; Jun, M; Manuel, D; Mavrakanas, T; McArthur, E; Molnar, AO; Rhodes, E; Sood, MM; Tanuseputro, P; Wells, P | 1 |
| Modukuru, VR; Naderan, M; Shoar, N; Shoar, S | 1 |
| Co, COC; Domingo, AMC; Iboleon-Dy, MAM; Ilano, KCS; Laxamana, LC; Macrohon-Valdez, MCZ; Mojica, CV; Yu, JRT | 1 |
| Bouchard, J; Brindamour, D; Charbonney, E; Dobrescu, MA; Dupuis, S; Flynn, F; Richard, G; Williamson, D | 1 |
| Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A | 1 |
| Gerasimenko, AS; Gorbatenko, VS; Shatalova, OV | 1 |
| Beasley, M; Brown, TM; Davis, BH; Dillon, C; Limdi, NA; McElderry, T; Narayan, R; Nolin, TD; Sangha, R | 1 |
| Chen, HY; Chou, KJ; Huang, CW; Lee, PT; Lin, PC; Ou, SH; Su, YC | 1 |
| Biyani, K; Guttendorf, R; Klaerner, G; Lee, A; Li, E; Mathur, V; Parsell, D; Shao, J; Stasiv, Y; Tabakman, S; Tsao, L; Wu, YS | 1 |
| Bo, M; Di Minno, G; Di Pasquale, G; Genovesi, S; Molteni, M; Toni, D; Verdecchia, P | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Davis, MDP; El-Azhary, RA; King, BJ; McBane, RD; McCarthy, JT; McEvoy, MT; Shields, RC | 1 |
| Baldovino, S; Fenoglio, R; Radin, M; Roccatello, D; Schreiber, K; Sciascia, S | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schüler, E; Schulman, S | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Ashley, J; Sood, MM | 1 |
| Hart, A; Shroff, GR; Stoecker, R | 1 |
| Banach, M; Covic, A; Lopatowska, P; Malyszko, J; Mlodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A | 1 |
| Jain, N; Reilly, RF | 1 |
| Ansell, JE; Blanco, R; Fonarow, GC; Freeman, JV; Gersh, BJ; Go, AS; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Naccarelli, G; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Singer, DE; Thomas, LE; Washam, JB | 1 |
| Arrigoni, L; Cappelletti, A; Cera, M; Colombo, A; Della Bella, P; Godino, C; Margonato, A; Mattiello, P; Mazzone, P; Melillo, F; Rubino, F; Salerno, A | 1 |
| Pastori, D; Violi, F | 1 |
| Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA | 1 |
| Ahmad, Y; Lip, GY | 1 |
| Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS | 1 |
| Collins, J; Eaddy, N; Lowe, MP; Yehia, M | 1 |
| González-Rico, MA; Juan-García, I; Miguel-Carrasco, A; Puchades-Montesa, MJ; Ramos-Tomás, C; Ribés-Cruz, JJ; Solís-Salguero, MA; Tejedor-Alonso, S; Tomás-Simó, P; Torregrosa-Maicas, I; Zambrano-Esteves, P | 1 |
| Expósito, V; Fernández-Fresnedo, G; Seras, M | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Cairns, JA; Connolly, S; Cox, JL; Dorian, P; Gladstone, D; Healey, JS; Ivers, N; Leblanc, K; Macle, L; McMurtry, MS; Mitchell, LB; Nattel, S; Stiell, IG; Verma, A | 1 |
| Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V | 1 |
| Harel, Z; Perl, J; Sood, MM | 1 |
| Narasimha Krishna, V; Rizk, DV; Saxena, N; Warnock, DG | 1 |
| Fanola, CL | 1 |
| Dagres, N; Hindricks, G; Jokic, V; Lane, DA; Larsen, TB; Lip, GY; Potpara, TS | 1 |
| Garg, AX; Gomes, T; Harel, Z; Juurlink, DN; Mamdani, M; Wald, R; Yao, Z | 1 |
| Pan, EY; Sobieraj, DM | 1 |
| Clemens, A; Formella, S; Huisman, MV; Janssen, M; Kooiman, J; Maas, H; Rabelink, TJ; van Buren, M; van der Hulle, T; Wiebe, S | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Glund, S; Grottke, O; Reilly, PA; Stangier, J; van Ryn, J | 1 |
| Granger, CB; Hawkins, NM; Jhund, PS; McMurray, JJ; O'Meara, E; Petrie, MC; Pfeffer, MA; Pozzi, A; Solomon, SD; Swedberg, K; Virani, S; Yusuf, S | 1 |
| Barcellona, D; Cianchetti, ME; Mameli, A; Marongiu, F; Musu, M; Porru, M; Ruberto, MF; Schirru, P | 1 |
| Balafa, O; Duni, A; Elisaf, MS; Kalaitzidis, RG; Liapis, G; Rapsomanikis, PK; Xiromeriti, S | 1 |
| Kolegova, II; Koziolova, NA; Polyanskaya, EA | 1 |
| Curtis, JA; Fellows, SE; Rosini, JM; Volz, EG | 1 |
| Dabage, N; Muniz, J; Paixao, R; Zaleski, M | 1 |
25 review(s) available for dabigatran and Chronic Kidney Diseases
| Article | Year |
|---|---|
Anticoagulant-related nephropathy: Focus on novel agents. A review.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2022 |
Newer Oral Anticoagulant in Chronic Kidney Disease: What we Should Know.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Renal Insufficiency, Chronic; Rivaroxaban | 2019 |
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism | 2020 |
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; Venous Thromboembolism; Warfarin | 2021 |
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Geriatrics; Hemorrhage; Humans; Metabolic Clearance Rate; Renal Insufficiency, Chronic; Warfarin | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thrombosis; Vitamin K | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Novel oral anticoagulants in chronic kidney disease: ready for prime time?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Venous Thromboembolism | 2018 |
Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cyclophosphamide; Dabigatran; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Male; Multimorbidity; Obesity; Prognosis; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Assessment; Rivaroxaban; Thromboembolism | 2018 |
Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2018 |
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Warfarin | 2019 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Monitoring, Physiologic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Stroke; Treatment Outcome | 2013 |
[Oral anticoagulation in chronic kidney disease with atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke | 2015 |
Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Renal Insufficiency, Chronic; Venous Thromboembolism; Vitamin K | 2015 |
Oral anticoagulants and risk of nephropathy.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Anticoagulants; Dabigatran; Disease Models, Animal; Humans; Rats; Renal Insufficiency, Chronic; Risk Factors; Warfarin | 2015 |
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Venous Thromboembolism; Vitamin K | 2015 |
Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Renal Insufficiency, Chronic; Stroke; Warfarin | 2016 |
Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Outpatients; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Clinical Trials, Phase I as Topic; Dabigatran; Hemorrhage; Humans; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Dabigatran; Female; Glomerulonephritis, IGA; Hematuria; Humans; Renal Insufficiency, Chronic; Risk Factors | 2017 |
3 trial(s) available for dabigatran and Chronic Kidney Diseases
| Article | Year |
|---|---|
Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2023 |
Assessment of the Potential for Veverimer Drug-Drug Interactions.
Topics: Absorption, Physicochemical; Acidosis; Administration, Oral; Adolescent; Adult; Aspirin; Cross-Over Studies; Dabigatran; Drug Interactions; Ethacrynic Acid; Female; Furosemide; Gastrointestinal Absorption; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Polymers; Polypharmacy; Renal Insufficiency, Chronic; Solubility; Warfarin; Young Adult | 2021 |
[The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial Fibrillation and Chronic Kidney Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2017 |
32 other study(ies) available for dabigatran and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cohort Studies; Dabigatran; Embolism; Humans; Ischemic Stroke; Renal Insufficiency, Chronic; Rivaroxaban; United States | 2022 |
Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2022 |
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2023 |
Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Renal Insufficiency, Chronic; Treatment Outcome | 2019 |
Expanding the Toolbox for Reversal of Anticoagulation in Chronic Kidney Disease.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Humans; Renal Insufficiency, Chronic | 2019 |
Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B; Atrial Fibrillation; Carboxylic Ester Hydrolases; Dabigatran; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Renal Insufficiency, Chronic | 2020 |
Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Prospective Studies; Renal Elimination; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2020 |
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Antithrombins; Brain Ischemia; Cause of Death; Comorbidity; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Myocardial Revascularization; Ontario; Procedures and Techniques Utilization; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Thrombophilia; Vitamin K | 2020 |
Regarding the publication "Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease".
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Warfarin | 2020 |
Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
Topics: Administration, Intravenous; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Hypertension; Male; Renal Insufficiency, Chronic; Stroke; Thrombolytic Therapy | 2020 |
Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Renal Replacement Therapy | 2022 |
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2020 |
[Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Treatment Outcome | 2020 |
Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.
Topics: Aged; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index | 2021 |
Direct oral anticoagulant medications in calciphylaxis.
Topics: Adult; Aged; Anticoagulants; Calciphylaxis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban | 2017 |
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Anticoagulants; Antithrombins; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Italy; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Statistics, Nonparametric; Treatment Outcome | 2019 |
Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Patients; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Safety | 2019 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Agents; Dabigatran; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome; Withholding Treatment | 2013 |
Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess.
Topics: Aged; Anti-Bacterial Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Decompression, Surgical; Epidural Abscess; Humans; Male; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Cord Compression; Treatment Outcome | 2013 |
Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease.
Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Mellitus, Type 2; Erythrocyte Transfusion; Female; Gastrointestinal Hemorrhage; Glomerular Filtration Rate; Humans; Hypertension; Metabolic Clearance Rate; Renal Dialysis; Renal Insufficiency, Chronic; Thrombophilia; Urinary Tract Infections | 2013 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clopidogrel; Comorbidity; Dabigatran; Electric Countershock; Humans; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine | 2014 |
Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Feeding Behavior; Female; Glomerular Filtration Rate; Humans; Male; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2015 |
Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Ontario; Renal Insufficiency, Chronic; Risk; Rivaroxaban; Warfarin | 2016 |
Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease.
Topics: Aged; Antithrombins; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index | 2016 |
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles | 2016 |
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Topics: Acute Disease; Aged; Atrial Fibrillation; Coma; Dabigatran; Drug Overdose; Heart Failure; Hemodiafiltration; Hepatitis; Humans; Male; Renal Insufficiency, Chronic; Stroke | 2017 |
Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency.
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Component Transfusion; Dabigatran; Emergency Service, Hospital; Endoscopy, Gastrointestinal; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Plasma; Pyridines; Renal Insufficiency, Chronic | 2013 |
Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Hyperkalemia; Kidney Transplantation; Male; Middle Aged; Renal Insufficiency, Chronic | 2013 |